<DOC>
	<DOCNO>NCT02401880</DOCNO>
	<brief_summary>The primary aim exploratory mechanistic study investigate effect Empagliflozin Linagliptin alpha- beta cell physiology T2DM patient . This study aim evaluate effect DPP-IV inhibitor linagliptin ( compare placebo ) addition SGLT-2 inhibitor empagliflozin pancreatic alpha beta cell function , well several marker metabolic control .</brief_summary>
	<brief_title>Effects Linagliptin Addition Empagliflozin Islet Cell Physiology</brief_title>
	<detailed_description>This study perform multi-center study include 2 centre . 44 subject T2DM include accord define in- exclusion criterion . Subjects stable metformin therapy receive first step empagliflozin 30 day . Both therapy ( metformin empagliflozin ) continue another 30 day subject randomize receive addition Linagliptin Placebo 30 day . Subjects come two inhouse period correspond study center undergo hyperglycaemic clamp test well Meal test period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>1 . Male female subject diabetes mellitus type 2 2 . Diabetes mellitus type 2 stable treatment metformin ( daily dose least 1000 mg ) least 6 month 3 . HbA1c 7.0 % 9.9 % , inclusive 4 . Diabetes duration least 24 month ) 1 . History diabetes mellitus type 1 2 . GFR ( calculate CockcroftGault equation ) &lt; 60 ml/min Screening 3 . Systolic blood pressure outside range 100160 mmHg diastolic blood pressure 95 mmHg Screening</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>